GHK-Cu vs Larazotide
Overview
GHK-Cu and Larazotide are both healing & recovery peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares GHK-Cu and Larazotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| GHK-Cu | Larazotide | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | Research use only |
| Typical dosage | 1-3 mg | 1-8 mg |
| Frequency | daily | three times daily |
| Reported benefits | Wound healing, collagen synthesis, anti-inflammatory, antioxidant effects, tissue remodeling | Reduces intestinal permeability, improves gut barrier function, celiac disease support |
| Reported side effects | Generally safe. Possible: mild skin irritation with topical use | Generally well-tolerated, possible headache |
Key differences
Primary use. GHK-Cu is categorised under Healing & Recovery, while Larazotide falls under Healing & Recovery. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. GHK-Cu: not FDA-approved; compounding permitted with a prescription as of April 2026. Larazotide: not FDA-approved; treated as a research compound.
Dosing. GHK-Cu is typically dosed at 1-3 mg (daily). Larazotide is typically dosed at 1-8 mg (three times daily).
Can you stack them?
Some protocols combine peptides, but stacking GHK-Cu and Larazotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between GHK-Cu and Larazotide?
- GHK-Cu and Larazotide are both healing & recovery peptides, but they differ in mechanism, dosing, and regulatory status. GHK-Cu is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Larazotide is not FDA-approved; generally classified as a research compound.
- What is GHK-Cu used for?
- Wound healing, skin regeneration.
- What is Larazotide used for?
- Gut permeability regulator.
- Can you take GHK-Cu and Larazotide together?
- Some users combine peptides within a single protocol, but stacking GHK-Cu and Larazotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is GHK-Cu or Larazotide FDA-approved?
- GHK-Cu is not FDA-approved; compounding permitted with a prescription (as of April 2026). Larazotide is not FDA-approved; generally classified as a research compound.
Read the full articles
- GHK-Cu — full monograph: mechanism, research, dosing & references
- Larazotide — full monograph: mechanism, research, dosing & references